The argument for using imatinib in CML

被引：32

作者：

Claudiani, Simone ^{[1
,2
]}

Apperley, Jane F. ^{[1
,2
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Clin Haematol, London, England

[2] Imperial Coll London, Ctr Haematol, London, England

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2018年

关键词：

CHRONIC MYELOID-LEUKEMIA; EARLY MOLECULAR RESPONSE; CHRONIC-PHASE; RANDOMIZED CML; FOLLOW-UP; FRONTLINE NILOTINIB; INTERIM ANALYSIS; DASATINIB; IMPACT; TRANSCRIPT;

D O I：

10.1182/asheducation-2018.1.161

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor (TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for patients with this disease is one of the major success stories of modem cancer medicine. The dilemmas that face physicians and patients are no longer only those concerned with delaying inevitable progression to the terminal blastic phase or selecting the individuals most likely to benefit from allogeneic stem-cell transplantation; rather, they are now focused also on the choice of TKI, the management of comorbidities and adverse effects, strategies to improve quality of life, and the appropriateness of a trial of therapy discontinuation. Interestingly, with 4 TKIs approved for frontline use, the choice of initial therapy continues to cause controversy, a situation made more complicated by the tantalizing prospect of treatment-free remission. In this manuscript, we will explore the factors influencing this decision and try to provide a pragmatic and clinically applicable solution.

引用

页码：161 / 167

页数：7

共 59 条

[1] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[2]

Barrientos JC, 2014, BLOOD, V124

[3] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].

Bower, Hannah ;

Bjorkholm, Magnus ;

Dickman, Paul W. ;

Hoglund, Martin ;

Lambert, Paul C. ;

Andersson, Therese M. -L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2851-+

[4] Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML [J].

Branford, Susan ;

Yeung, David T. ;

Ross, David M. ;

Prime, Jodi A. ;

Field, Chani R. ;

Altamura, Haley K. ;

Yeoman, Alexandra L. ;

Georgievski, Jasmina ;

Jamison, Bronte A. ;

Phillis, Stuart ;

Sullivan, Brad ;

Briggs, Nancy E. ;

Hertzberg, Mark ;

Seymour, John F. ;

Reynolds, John ;

Hughes, Timothy P. .

BLOOD, 2013, 121 (19) :3818-3824

[5]

Breccia M, 2017, ONCOTARGET, V9, P7534

[6]

CALDWELL L, 2017, BLOOD S1, V130

[7] The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib [J].

Castagnetti, Fausto ;

Gugliotta, Gabriele ;

Breccia, Massimo ;

Iurlo, Alessandra ;

Levato, Luciano ;

Albano, Francesco ;

Vigneri, Paolo ;

Abruzzese, Elisabetta ;

Rossi, Giuseppe ;

Rupoli, Serena ;

Cavazzini, Francesco ;

Martino, Bruno ;

Orlandi, Ester ;

Pregno, Patrizia ;

Annunziata, Mario ;

Usala, Emilio ;

Tiribelli, Mario ;

Sica, Simona ;

Bonifacio, Massimiliano ;

Fava, Carmen ;

Gherlinzoni, Filippo ;

Bocchia, Monica ;

Soverini, Simona ;

Bochicchio, Maria Teresa ;

Cavo, Michele ;

Giovanni, Martinelli ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Baccarani, Michele ;

Rosti, Gianantonio .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) :797-805

[8] De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].

Clark, Richard E. ;

Polydoros, Fotios ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Pocock, Christopher ;

Smith, Graeme ;

Byrne, Jenny L. ;

de lavallade, Hugues ;

O'Brien, Stephen G. ;

Coffey, Tony ;

Foroni, Letizia ;

Copland, Mhairi .

LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316

[9] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Pinilla-Ibarz, Javier ;

le Coutre, Philipp D. ;

Paquette, Ronald ;

Chuah, Charles ;

Nicolini, Franck E. ;

Apperley, Jane F. ;

Khoury, H. Jean ;

Talpaz, Moshe ;

DeAngelo, Daniel J. ;

Abruzzese, Elisabetta ;

Rea, Delphine ;

Baccarani, Michele ;

Mueller, Martin C. ;

Gambacorti-Passerini, Carlo ;

Lustgarten, Stephanie ;

Rivera, Victor M. ;

Haluska, Frank G. ;

Guilhot, Francois ;

Deininger, Michael W. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Shah, Neil P. ;

Kantarjian, Hagop M. .

BLOOD, 2018, 132 (04) :393-404

[10] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial [J].

Cortes, Jorge E. ;

Gambacorti-Passerini, Carlo ;

Deininger, Michael W. ;

Mauro, Michael J. ;

Chuah, Charles ;

Kim, Dong-Wook ;

Dyagil, Irina ;

Glushko, Nataliia ;

Milojkovic, Dragana ;

le Coutre, Philipp ;

Garcia-Gutierrez, Valentin ;

Reilly, Laurence ;

Jeynes-Ellis, Allison ;

Leip, Eric ;

Bardy-Bouxin, Nathalie ;

Hochhaus, Andreas ;

Brummendorf, Tim H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :231-+

← 1 2 3 4 5 6 →